All In Biotech

Drug Trial Radar · NCT07537387

A Study on the Pursuit of Sustained Clearance of HBsAg in Chronic Hepatitis B(CHB) Patients With Previous Interferon Treatment Using Pegylated Interferon Alpha

A Prospective, Non-Randomized, Multicenter Study of Peginterferon Alfa for Pursuing Sustained Hepatitis B Surface Antigen(HBsAg) Clearance in Interferon-Pretreated Patients With Chronic Hepatitis B

Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

10,000

Planned (sponsor's estimate)

Start

Apr 30, 2026

Primary completion

Dec 31, 2029

Study completion Dec 31, 2030

Sponsor

Lead sponsor
xieqingAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 17, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years

Summary

As written by the sponsor on the registry.

This is a real-world, prospective, multicenter, non-randomized, controlled study. It aims to investigate the efficacy and safety of pegylated interferon α-2b (PEG IFN α-2b) monotherapy versus its combination with nucleos(t)ide analogs (NAs) regarding hepatitis B surface antigen (HBsAg) clearance in interferon-experienced patients with chronic hepatitis B (CHB). Subjects will receive either interferon-based therapy or NAs monotherapy based on their personal willingness and physicians' professional recommendations, with a uniform 48-week treatment course for all enrolled patients.

Conditions

  • Chronic Hepatitis b

Interventions

  • PEG IFNα-2b monotherapy or combination therapy with NAsDrug

    Peginterferon α-2b injection, 180mcg, s.c, once a week, for 48 weeks.If HBV DNA is below the lower limit of detection at baseline (highly sensitive assay is recommended), PEG IFNα-2b monotherapy will be administered.

  • NAs monotherapy groupDrug

    Peginterferon α-2b injection, 180mcg, s.c, once a week, for 48 weeks.If HBV DNA is below the lower limit of detection at baseline (highly sensitive assay is recommended), PEG IFNα-2b monotherapy will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with undetectable HBsAgTime frame: Week 48
  2. Percentage of subjects with undetectable HBV DNATime frame: Week 48

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.